MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with E

Erythromycin stearate

Erythromycin stearate 250mg tablets

Use with caution

Stability notes for Erythromycin stearate 250mg tablets

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Erythrocin 250 tablets (Advanz Pharma).

Suppliers

Erythrocin 250 tablets (Advanz Pharma)
Erythrocin 250 tablets (CST Pharma Ltd)

Erythromycin stearate 500mg tablets

Use with caution

Stability notes for Erythromycin stearate 500mg tablets

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Erythrocin 500 tablets (Advanz Pharma).

Suppliers

Erythrocin 500 tablets (Advanz Pharma)
Erythrocin 500 tablets (CST Pharma Ltd)
Erythrocin 500 tablets (Sigma Pharmaceuticals Plc)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.